Health TrialsbyHealthPanel

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Clinical Study of CHT105 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

Primary Objective: To evaluate the safety and efficacy of CHT105 Injection in subjects with relapsed/refractory autoimmune diseases. Secondary Objective:To evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of CHT105 Injection. Indication: Immune Thrombocytopenia (ITP)

Participants needed: 24
Trial details
Age: 18-65Biological sex: AllType: InterventionalSponsor: Nanjing Miracle Biotechnology Co., Ltd.Updated: Sep 10, 2026Locations: 1
Eligibility criteria

Age ≥18 and ≤65 years (inclusive), no restriction on gender; [+1]

Subjects with a severe history of drug allergy or allergic diathesis; [+11]

Read more
Status: Not yet recruiting

A Phase I, Single-Arm, Open-Label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of CHT101 Injection in Subjects With Relapsed/Refractory T-Cell and B-Cell Hematological Malignancies

Primary Objective: To evaluate the safety, tolerability, and dose-limiting toxicity of CD70-targeted chimeric antigen receptor allogeneic T-cell injection (CHT101) in the treatment of subjects with CD70-positive relapsed/refractory T-cell and B-cell hematological malignancies. Primary Endpoint: MTD, RP2D or biologically effective dose; to assess the incidence, severity and relatedness of AEs and SAEs. Indication: CD70-positive relapsed or refractory T-cell and B-cell hematological malignancies

Participants needed: 30
Trial details
Phase: Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: Nanjing Miracle Biotechnology Co., Ltd.Updated: Sep 9, 2026Locations: 1
Eligibility criteria

Prior to performing any study-related assessments/procedures, understand and vol... [+7]

Central nervous system (CNS) metastasis, leptomeningeal disease or metastatic sp... [+37]

Read more
Status: Not yet recruiting

A Clinical Study to Evaluate CHT101 Injection in Subjects With Relapsed/Refractory T-Cell and B-Cell Hematologic Malignancies

Primary Objective: To evaluate the safety, tolerability, and dose-limiting toxicity of anti-CD70 chimeric antigen receptor allogeneic T-cell injection (CHT101) in the treatment of CD70-positive relapsed/refractory T-cell and B-cell hematological malignancies. Secondary Objectives: To characterize the PK profiles of CHT101; to evaluate the clinical efficacy of CHT101 for CD70-positive relapsed/refractory T-cell and B-cell hematological malignancies. Indication: CD70-positive relapsed/refractory T-cell and B-cell hematological malignancies

Participants needed: 30
Trial details
Phase: Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: Nanjing Miracle Biotechnology Co., Ltd.Updated: Sep 9, 2026Locations: 1
Eligibility criteria

Understand and voluntarily provide written informed consent (ICF) prior to any s... [+11]

Central nervous system (CNS) metastasis, leptomeningeal disease or metastatic ce... [+22]

Read more